Poly Medicure Limited
1,448.90
INR
-21.20
(-1.44%)
ISIN
INE205C01021
Return %
Stock
S&P 500
1Y
-25.11
14.20
3Y
4.74
81.12
5Y
57.54
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Himanshu Baid
- Full Time Employees
- 2,614
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 232B Okhla Industrial Estate New Delhi DE India 110020
- IPO Date
- Dec 5, 2011
- Website
- polymedicure.com
- Similar Companies
- Business
- Poly Medicure Limited operates as a manufacturer and exporter of medical devices headquartered in Delhi, India. Established in 1995, the company offers an extensive portfolio of over 200 medical device products spanning 12 therapeutic categories including infusion therapy; anesthesia and respiratory care; oncology; urology; gastroenterology; blood management and blood collection; surgery and wound drainage; dialysis and renal care; central venous access devices; critical care; cardiology; transfusion; and veterinary medical devices. Key product offerings include I.V. cannulas, arterial cannulas, prefilled syringes, nasogastric and gastro-duodenal feeding tubes, umbilical catheters, irrigation sets, urine drainage catheters, blood bag systems, dialysis consumables and machines, ventilator circuits, suction catheters, and implantable ports among others. Its products are marketed internationally, reaching over 125 countries, with significant export operations alongside domestic sales in India. Recent developments reflect strategic expansion and capacity additions aimed at growth acceleration and portfolio enhancement. In 2025, Poly Medicure completed the acquisition of Pendracare International BV and announced the acquisition of MediStream SA, which includes Citieffe SRL, thereby entering the global orthopedics market with a focus on trauma products and expanding its European and global distribution networks. The company invested in commercializing four new manufacturing facilities in fiscal year 2024, which are expected to double production capacity over the next four to five years. It continues to expand its research and development pipeline with 20-30 new products in development and plans for launching 10-12 new products annually, particularly focusing on higher-value and complex differentiated medical devices. The company targets growth in domestic and international markets, leveraging government policy changes favoring local manufacturing, and aims to increase market share in interventional cardiology, renal, and critical care segments. Poly Medicure competes with multinational medical device companies such as B Braun, Nipro, and Becton Dickinson, emphasizing innovation, broad therapeutic coverage, and operational expansion. The company serves hospitals, healthcare providers, and distributors in both emerging and established markets, with a strategic focus on increasing hospital penetration and sales per hospital. Its operational footprint includes manufacturing units in India and a growing international presence supported by strategic acquisitions and partnerships. Poly Medicure is positioned for sustained revenue growth driven by base demand, product innovation, manufacturing scale-up, and geographic expansion into new therapeutic and regional markets.